IC51 + JE-VAX
Phase 3Completed 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Japanese Encephalitis
Conditions
Japanese Encephalitis
Trial Timeline
Sep 1, 2005 → Sep 1, 2006
NCT ID
NCT00604708About IC51 + JE-VAX
IC51 + JE-VAX is a phase 3 stage product being developed by Valneva SE for Japanese Encephalitis. The current trial status is completed. This product is registered under clinical trial identifier NCT00604708. Target conditions include Japanese Encephalitis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00604708 | Phase 3 | Completed |
Competing Products
20 competing products in Japanese Encephalitis